This site is intended for health professionals only
Monday 27 May 2019
Share |

Settlement over atorvastatin

Astellas Pharma emerges victorious in lawsuit over atorvastatin

A settlement has been reached between Pfizer and Astellas Pharma in Japan over blockbuster cholesterol drug atorvastatin (Lipitor), with Astellas Pharma wining the dispute and retaining the rights to market the treatment until July 2016.

A lawsuit was filed by Astellas in November 2006, after Pfizer affirmed that the Japanese firm's licence only ran until 2001, when the substance patent expires in Japan. Astellas licensed atorvastatin from Warner-Lambert before it merged with Pfizer, and the product was launched on the Japanese market in 2000.

Although the settlement involved no payments, keeping hold of the world's best-selling drug is good news for Astellas.

Ads by Google

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine